The Most Important Cannabis Trends Of 2019

FN Media Group Presents Market Commentary


London – July 11, 2019 – Not too long ago, cannabis was just the feel-good supplement of choice for a young generation, looking to blow off steam. But intense research on the plant has led to new discoveries. Today, cannabis is used not only to blow off some steam, but to treat diseases which effect the immune system, pain and inflammation, seizures and even mental disorders.  Mentioned in today’s commentary includes:  Supreme Cannabis (OTCQX:SPRWF) (TSX:FIRE), Auxly Cannabis (OTCQX:CBWTF) (TSX-V:XLY), Constellation Brands (NYSE:STZ), Emerald Health Therapuetics (OTCQX:EMHTF) (TSX-V:EMH), MedMen Enterprises (OTCQX:MMNFF) (CSE:MMEN).


Cannabis is finally becoming globally recognized as a viable alternative to costly, ineffective and sometimes dangerous medicines. And thanks to this, not only are a lot of people getting the help they truly need, an entire industry is growing right in front of our eyes.


This destigmatization has led to marijuana use across the United States and Canada growing substantially over the past 10 years. Across all age groups and demographics. And while it is already legal, and blossoming, in Canada, the push to bring cannabis into mainstream markets in the United States is catching fire. In a big way.


Even in the most conservative states in America, the veritable wunderdrug is being legalized. Take Oklahoma, for example. Medical marijuana was legalized in the state just last year, and within months, state regulators were swamped with permit requests and demand for medical cards. But that’s only half the story.


Recreational cannabis is also gaining traction across the nation. Many states in the East Coast are already in the process of lifting regulations to accommodate the overwhelming demand of their constituents. And as the most densely populated region in the country, that means already-established cannabis companies are just waiting for go-ahead before the next ‘green rush’ begins.


But legalization – both medical and recreational – is the most obvious trend in this emerging market. Cannabis is a fast-moving market. New tech, new products, new regulations and new consumers are sprouting up every day. And because of this, it’s a very lucrative space for early investors who can identify these emerging trends.


Here are the three most important emerging trends in the cannabis market today (and the companies leading the charge):


The CBD Health and Wellness Explosion


Most people know what THC is, or at least how it impacts people. It’s the compound in cannabis that leaves users feeling giddy, goofy, and, well, stoned. Think Snoop Dogg or Cheech and Chong. But that’s not the end of the story for cannabis.


In recent years, researchers have perfected the art of extracting another compound – CBD (cannabidiol). Why? Because it offers all of the amazing medical benefits associated with cannabis, without the glassy eyes and uncontrollable bursts of laughter. And consumers can’t get enough of it.


From migraines to depression, as the legal floodgates open, consumers are buying up every new product hits the market. And smart cannabis companies are happy to help.


One of the companies leading this charge is Supreme Cannabis (OTCQX:SPRWF) (TSX:FIRE). Supreme is looking at the world stage as this new market develops. With a global vision and the drive to pursue this opportunity, Supreme is already carving out its market share in key regions as new regulation is passed.


Recently, the company launched its UK-based investment arm Supreme Heights, a platform created for the sole purpose of identifying and capitalizing on opportunities in the UK and Europe’s CBD health and wellness market.


Navdeep Dhaliwal, CEO of Supreme Cannabis explained, “The rapidly evolving CBD markets in the UK and Europe present compelling investment opportunities given the promising environments for new health and wellness companies to establish differentiated brands and capture meaningful market share.”


But other companies, like Auxly Cannabis (OTCQX:CBWTF) (TSX-V:XLY), are taking a slightly different – more local – approach. As a veteran in the Canadian market, Auxly has positioned itself ahead of the competition in the coming U.S. market boom thanks to its ambitious wheeling and dealing across Canada. With ample supply, a strong distribution platform, extraction tech and regulatory knowledge, Auxly is ready to pounce.


And Auxly’s expansion isn’t slowing anytime soon. Recently, the company even secured cultivation and processing licenses at a new 27,700 square-foot facility. The new venture is said to focus on premium strains, offering nothing but the best products.


Hugo Alves, President of Auxly explained, “This is a big milestone for one of our key subsidiaries and member of the Auxly family. We know that Andrew and his team are going to produce some of the best cannabis flower available in Canada and we can’t wait to share it with Canadian consumers.”


Big Data and Supply Chain Management


What’s the genius of Amazon? Simple: control of information. Jeff Bezos turned a little online book store into one of the world’s most valuable corporate behemoths by applying technological solutions to complex problems—creating a model mirrored around the world.


Now, a little-known company is trying to duplicate that feat. TruTrace Technologies (TTT.CN – TTTSF) is helping other companies “Amazonify” their businesses— creating a niche in the tech world that has yet to be filled. In other words, it has no competitors yet.


As any retail firm knows, distribution is essential—it can be the biggest source of additional costs and the perfect place to improve efficiency. Inefficiency can be a killer—a study from 2012 showed that distribution centers lose 3000 hours a year to unproductive workflow. Lack of control over information costs even more—large businesses lost $47 million per year to inefficiencies in data transfer.


That’s where TruTrace Technologies comes in. The company has developed a unique platform to help companies cut costs, streamline marketing and distribution procedures, and eliminate inefficiency in the supply chain.


It’s all about finding the best tech to fit the problem—and TruTrace Technologies has built a sturdy platform that covers an entire industry’s supply chain, from top to bottom. Plus, the company’s working in an exciting, rapidly growing new industry—cannabis.


TruTrace Technologies is breaking into cannabis, but it’s got the potential to take on much bigger markets—including retail groceries, which is currently dominated by big supermarket chains like Kroger Company ($105 billion) and H.E.B. ($21 billion).


And where other cannabis plays have focused on production—which firms have the most product, the lowest prices, the biggest chunk of market—TruTrace (TTTTTTSF) hopes to make a splash by tackling the issues surrounding the emergence of a new market—one that could be worth billions of dollars.


For TruTrace, the possibilities for growth are extremely attractive. They already have the attention of the large medical community in the Canadian market-place and some in the US market-place.


Joint Ventures and M&As


Currently, corporate tie-ups are all the rage in the marijuana sector. Mostly it’s been big pot and big tobacco buying marijuana companies in multi-billion-dollar deals in the hope of getting a piece of the action.


  • Constellation Brands (NYSE:STZ) invested $4 billion investment into Canopy Growth Corporation
  • Altria Group Inc. has agreed to take a $1.8B minority stake in Cronos Group Inc.
  • Aurora Cannabis Inc  has agreed to buy smaller rival CanniMed Therapeutics Inc. for C$1.1 billion ($852 million.


And while giant brands get all of the attention, other smaller companies, like Emerald Health Therapuetics (OTCQX:EMHTF) (TSX-V:EMH) are flying under the radar. As a veteran in the cannabis sector, Emerald has placed a lot of emphasis on its strategic partnerships and acquisitions.  With a highly experienced team in life sciences and product development, the company is truly carving out a name for itself.


Emerald’s reach expands through virtually every sub-sector of the cannabis industry, including cultivation, product development, research, and pharmaceutical solutions. But one of its most unique qualities is that it does not limit itself to pure-cannabis deals.


Emerald recently launched a new product line aiming to support the endocannabinoid system to help maintain equilibrium in the body. Dr. Gaetano Morello, Naturopathic Doctor, CEO of Emerald Health Naturals explained, “The Endo product line was developed by leading naturopathic doctors who previously launched new products into the natural health market, and we are pleased to now introduce Canadian consumers and retailers to this new nutritional supplement as an alternative to existing drugs, supplements, and cannabis.”


Hexo, previously Hydropothecary, is also making some major moves in the M&A wave. The company, which is engaged in the production, distribution and marketing of cannabis and cannabis products, made headlines after it secured a huge deal with international beverage giant Molson Coors. The joint venture marked a new era in recreational marijuana, bringing two heavyweight industries together under one roof.


HEXO’s CEO and co-founder Sebastien St-Louis, explained, “As two leading companies who share a track record of excellent practices, as well as respect for law and regulations, HEXO and Molson Coors Canada have established a relationship built on trust, and together we will develop responsible, high-quality cannabis-infused beverages for the consumable cannabis market in Canada.”


While most of the major pot-stock news comes from Canada, one of the industry’s top wheelers and dealers actually comes from California. MedMen Enterprises (OTCQX:MMNFF) (CSE:MMEN) is quietly gaining traction in the U.S. market, largely thanks to its strategic acquisitions and focus on expanding its domestic footprint.


In just a year, MedMen has closed on two major deals, including its buyout of California-bases retailer One Love and its acquisition of medical-marijuana provider PharmaCann.  The PharmaCann deal, in particular, solidified MedMen’s position as an ‘up-and-comer- to watch. The $682 million acquisition made headlines as the largest marijuana deal at the time, with many analysts praising it as a major steal for MedMen.




PAID ADVERTISEMENT. This communication should be viewed as a paid advertisement. Leacap Ltd and Safehaven and their owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher was not specifically paid for this communication.  However, a related company was previously compensated by TruTrace Technologies In May 2018, to produce and disseminate other similar articles and certain banner ads. This compensation should be viewed as a major conflict with our ability to be unbiased.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.


SHARE OWNERSHIP. The owner of Safehaven owns shares and/or stock options of the featured companies and therefore has an additional incentive to see the featured companies’ stock perform well. The owner of Safehaven has no present intention to sell any of the issuer’s securities in the near future but does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The owner of Safehaven will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.


FORWARD LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Factors that could cause actual results to differ include, but are not limited to, changing governmental laws and policies, the success of the companies’ technology, the size and growth of the market for the companies’ products and services, the companies’ ability to fund their capital requirements in the near term and long term, pricing pressures, etc.


INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.


TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://Safehaven/terms-and-conditions If you do not agree to the Terms of Use http://Safehaven/terms-and-conditions, please contact Safehaven to discontinue receiving future communications.


INTELLECTUAL PROPERTY. Safehaven is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.



DISCLAIMER: is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with or any company mentioned herein.  The commentary, views and opinions expressed in this release by are solely those of and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.



This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact – FN Media Group LLC


U.S. Phone: +1(954)345-0611